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The Past Is the Future
Innovative Designs in Acute Stroke Therapy Trials
Michael Krams, MD; Kennedy R. Lees, MD; Donald A. Berry, PhD
More than 74 0001 patients with acute ischemic strokehave been randomized into clinical trials over the past
35 years to investigate new therapies.1 Only one treatment,
thrombolysis with recombinant tissue plasminogen activator,
has emerged from these investigations.2 Efforts to establish
acute neuroprotectant therapies have yet to succeed.3,4
Have we squandered our resources? Has methodological
rigidity delayed development of a new treatment or prolonged
investigation of an ineffective therapy? Here we present a
flexible and more efficient approach to clinical trial design
and analysis. We have the potential to improve the use of
scarce patient resources and to accelerate development of
promising agents.
In medical practice, we respond to a patient if a dosage
seems inadequate by either changing the dosage or switching
to another medication. We cautiously change treatment after
reviewing new evidence: side effects, intractable symptoms,
and poor adherence. We might express our estimate of how
much the change may improve the patient’s condition in
terms of probability. We repeat this process every time we
update the treatment plan in light of new important informa-
tion. Why not take the same approach to clinical trials?
The proposed approach to the design and conduct of
clinical trials uses Bayesian methods that make careful use of
high-quality available past (prior) evidence to refine the
inference from accumulating evidence in the ongoing clinical
trial. This approach may: (1) enhance investigation of single
agents or combination therapies; (2) make earlier and more
reliable choices of dose for use in pivotal trials; (3) accelerate
the progression from phase II into phase III trials all the way
to a potentially seamless switch; and (4) treat trial participants
more effectively by adaptively allocating more resources to
therapies that are performing well while reducing support for
less promising treatment arms.
Concepts
The basis of all statistical inference is probability. The
frequentist approach to inference deals with probabilities of
data for given hypotheses or particular values of unknown
parameters. Bayesian probabilities apply as well to hypothe-
ses and parameters themselves.5 The difference is critical.
The Bayesian approach is tailored to learning on the basis of
evidence. Bayesian probabilities can be calculated at any time
and can be updated continually as information becomes
available.
A consequence of the Bayesian approach is the ability to
calculate probabilities of the results of future observations
given the current uncertainty in the parameters. For example,
predictive probabilities allow for addressing whether and
which observation to take next. This ability is fundamental in
designing experiments.
The Bayesian approach is tailored to making decisions.
Designing a clinical trial is a decision problem. Optimal
designs are those that maximize gain. Gain or loss depends on
the goals of the designer. For example, the goal may be to
deliver a good medicine.
Bayesian designs can be arbitrarily complicated. However,
with computer power available today, even very complicated
designs can be simulated many thousands of times. This
allows for evaluating the design’s false-positive rate and
other operating characteristics that are usually viewed as
being frequentist measures. The design might be modified to
have operating characteristics that are acceptable to regula-
tory or funding agencies. In a sense, this strategy is using the
Bayesian approach as a tool for building a good frequentist
design.
Bayesian Applications
Bayesian methods and decision theory are widely used in
medicine and industry. A number of medical devices have
been approved by the Food and Drug Administration on the
basis of Bayesian experimental designs and analyses. Many
phase I and II oncology trials have been designed and
conducted at M. D. Anderson Cancer Center from the
Bayesian perspective.6,7 An example is a trial that uses
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adaptive randomization in which patients are more likely to
be assigned treatments that are performing better in the trial.8
Historical Data
Our first step to designing a stroke study is to assess existing
data and to model potential trial outcomes. Despite different
treatment strategies prior information can be incorporated
into a hierarchical model that will combine these existing data
with the future results of the trial being planned.6–9 The term
“hierarchical” indicates how differences in design are ex-
pressed. The more similar designs tend to lie close to the top
of hierarchical model. The model also contains terms that
increase the variance and hence express the uncertainty
among dissimilar studies.
The ASTIN trial provides a good example for the use of
historical data.10 To predict likely recovery profiles of stroke
patients over a 90-day period, based on initial severity, under
the assumption of “no experimental treatment,” data from the
Copenhagen Stroke Study11 were used to model physiological
recovery in untreated acute stroke patients (Figure 1).12 Real
data from the trial would gradually be introduced to update
this “longitudinal model.”
A wealth of high-quality data lies dormant that could be
used to inform the design and conduct of future stroke
trials. The Virtual International Stroke Trials Archive
(VISTA) offers a mechanism for accessing valuable data
sets and using them to benefit future patients: entire stroke
trial data sets or records from placebo groups can be
documented, securely stored, and, subject to approval by a
committee of original investigators and sponsors, accessed
for analysis. VISTA involves data from a wide range of
countries, sites, and trials and reflects the natural history of
patients recruited into stroke trials. Stroke trialists are
invited to contribute to and utilize this resource (contact
K.R.L., k.r.lees@clinmed.gla.ac.uk).
The Bayesian Approach
The Bayesian approach is one of continual learning. Instead
of the current practice of leaving information accruing during
a trial untouched in a sealed database as the trial progresses,
we make immediate use of it. Our knowledge base is
continuously updated, and aspects of the trial design such as
allocation of patients to certain dosage levels are gradually
modified. The accruing data changes our levels of uncertainty
as expressed by probability estimates. A prior estimate of the
probability of an uncertain event is updated to a posterior
probability each time a new piece of information becomes
available.6,7,9 This continuous learning need not be transpar-
ent to investigators or anyone in a position of influence over
the trial: the decision tree can be built in advance and
“delegated” to a computer, which is closely supervised by an
independent data monitoring committee, as in ASTIN.
Adaptive Designs
Insufficient understanding of the dose–response and inappro-
priate choice of doses taken into confirmatory studies plague
drug development. Lubeluzole is one example of a neuropro-
tective drug development program that would have benefited
from better understanding of the dose–response: plasma
levels of lubeluzole achieved in the pivotal trials were lower
than those necessary for neuroprotection in experimental
models.13 In retrospect, a different phase II trial design and
incorporation of information from the experimental situation
may have improved the choice of dose for pivotal trials or
prevented considerable unnecessary expense and use of
resources by terminating the program early.
We illustrate the benefits of modeling and using a Bayesian
adaptive design for efficient learning about the dose–
response12 with ASTIN10 as an example. Parallel group
designs often test only a small number of treatment arms,
comparing them against placebo. Suppose the objective is to
identify the minimal dose yielding near-maximal efficacy
(ED95). The appropriate dose can never be found more
accurately than the distance between the doses studied. It
helps to increase the number of doses: in ASTIN there were
16. However, a traditionally powered design with 16 arms
would be enormous. Adaptive treatment allocation in a
sequential design is more efficient: outcome data accrue in
Figure 1. “Longitudinal model.” Relation-
ship between early response and final
outcome in untreated acute stroke
patients. Data from Copenhagen Stroke
Study.9 Stroke severity as measured on
Scandinavian Stroke Scale (SSS) (0:
comatose patient; 58: no gross neuro-
logical deficit). Each circle represents 1
patient. Y-axis: SSS at discharge from
stroke unit. X-axis: SSS at earlier time
points. Black line: linear regression
through the data. A, SSS at admission
does not correlate strongly with SSS at
discharge. However, there is partial infor-
mation even at baseline. Patients with
mild strokes tend to do well (cloud in
right upper corner), whereas patients
with severe strokes tend to do poorly
(left lower corner). B, SSS at week 1 vs
discharge. C, Week 4 vs discharge. D,
Week 8 vs discharge. Over time there is
an increasingly strong relationship
between the SSS score at an earlier time
point and time of discharge.
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real time, the data are modeled to estimate the dose–response,
and our decision as to which treatment to allocate to the next
patient is conditional on the latest updated estimate of the
dose–response (Figure 2). Patients will preferentially be
allocated to informative treatment arms. The goal is to close
in on the appropriate dosage level and then efficiently
minimize the variance about a parameter of interest. In
ASTIN we chose to minimize the variance around the point
estimate of the treatment effect at the estimated ED95. In
other words, we concentrated our effort around doses that
seemed to produce near-maximal efficacy. We can explore a
wide range of possible doses at the start of the trial without
having to waste patients on treatment arms with low infor-
mation value later in the trial.
Thanks to high-speed computing, adaptive treatment allo-
cation is not limited to one-dimensional problems. Figure 3
illustrates simulated examples of learning about the dose–
response (surface) for a single investigational drug and a
combination of 2 drugs.
Termination Rules
In drug development, most projects fail. It would be prefer-
able to stop failing clinical trials as soon as possible. When
successful in finding a dose that provides clinically meaning-
ful benefit, we would prefer a rapid transition from dose–
response exploration to a confirmatory study. Although
traditional designs permit a few interim analyses for futility,
the Bayesian approach as applied in ASTIN feature continu-
ous reassessment of the data, with a computer algorithm
advising an Independent Data Monitoring Committee
(IDMC) on whether to continue or stop the trial. At the start
of the trial, there is great uncertainty around our estimates of
dose–response and ED95, but as trial data accrue, this
uncertainty shrinks. The stopping rule in ASTIN continuously
asked the following questions: (1) Does our estimate of the
dose–response suggest that there is 10% chance of success
for any dose (success was defined as a 3-point recovery
over and above placebo as measured by a stroke scale)? If so,
then stop for futility. (2) For the best dose, is the response
good enough to conclude that there is 90% chance of
success? If so, then stop for efficacy and switch to a
confirmatory trial, comparing the “best dose” against
placebo.
We considered, but did not use, a more sophisticated
decision–theoretic approach to stopping the trial.12 Clinical
practice and clinical research involve making decisions, eg,
choosing sample size. It is impossible to precisely predict the
consequence of a particular decision. But it is possible to
associate a predictive probability to each possible result and
its consequence. A numerical assignment to a consequence
indicating the overall value of a consequence is called a
“utility.” Economists distinguish utility from dollar value
because realistic values also depend on the usefulness of the
consequence. The utility of any particular consequence of a
clinical trial design should reflect its consequent impact on
patients with the disease, including patients inside and outside
the trial.14 Say that we could define the value of a successful
treatment to any one stroke patient to whom it would be
deployed. A decision–theoretic stopping rule would ask:
Where can each individual patient contribute maximal value,
in the trial learning about the dose–response or in a confir-
matory trial? Clearly, the traditional p-value seldom reflects
utility, but rather serves only to provide a common standard.
Ethically, the utility approach is appealing. Its focus is the
overall set of patients with stroke, trying to maximize the
value of each patient entering clinical research programs to
optimize treatment for the overall population and the individ-
ual patients. For a more detailed discussion, see Lewis et al15
and Cheng et al.16
Simulation-Guided Trial Design
Computer simulation of clinical trials can help to improve the
final design and learn about its characteristics. A Bayesian
approach requires an initial alignment of assumptions and
agreement on which models to use. Early interactions with
Figure 2. Design for response-adaptive learning about the dose–
response with dynamic termination rule. Data on the primary end-
point is captured in real time. The accruing data are continuously
reassessed to help with 2 decision problems. (1) To which treat-
ment should the next patient be allocated to optimize learning
about the research question (dose–response, ED95)? (2) Should
the study continue to accrue information or is there sufficient data
to stop the trial either for futility or efficacy? The diagram follows
the passage of 1 patient through the system. In reality, several
patients will be progressing through the system at any one time
and the database will contain data on commencing, ongoing, and
complete patients. [1] that the patient presents for randomization
(baseline data are wired into system); [2] Patient is randomized in
blinded fashion to placebo or “optimal” dose to learn about
research question; [3] Dose assigned is converted to particular vial
numbers, allowing for blinded administration of study drug; [4]
Patient’s response data are entered into the system as they
progress through the study; [5] Patient’s final outcome is predicted
using a longitudinal model (see Figure 1) (the prediction is substi-
tuted by the final response, as soon as it becomes available); [6]
Based on the currently available data, the system updates the
“estimate” of the dose response curve and its uncertainty; [7] Each
day the algorithm implements a decision rule and recommends to
either: [8] A0: stop the study because of futility (based on the pos-
terior probability that the treatment has an effect smaller than a
minimum clinically relevant size) or [9] A2: stop dose finding and
moves to a large confirmatory study (based on the posterior prob-
ability that the treatment has an effect larger than some clinically
relevant size); [10] A1: continue dose finding study (the recommen-
dation of the system is reviewed by the IDMC, which incorporates
clinical judgment and factors in safety issues); [11] The dose allo-
cator chooses a dose from a list of possible doses that will opti-
mize learning about the ED95 or some aspect of the dose–re-
sponse curve. The database used to determine the dose is
continually updated as outcome data from patients are gathered.
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relevant experts, including statisticians, clinicians, and regula-
tors, can establish credible models and simulation can sort
through possible scenarios to find the potentially best design. In
developing and optimizing the design for ASTIN, hundreds of
thousands of stroke trials were simulated. We confirmed that the
design would perform to specification (eg, correctly adapt
treatment allocation according to dose–response, learn about
dose–response efficiently, choose the correct ED95, and stop
early for the right reasons). The design was tested under extreme
circumstances, including scenarios in which the true dose–
response curve was flat, sigmoid, or up–down; different patient
recruitment speeds; and different thresholds for futility and
efficacy. Frequentist statistical characteristics such as type I and
II error rates were adjusted and confirmed using Monte Carlo
simulation. Even during the conduct of ASTIN, the IDMC
undertook additional simulations to satisfy themselves that some
of the responses they were seeing would be correctly handled by
the computer algorithm.
Figure 3. Response-adaptive treatment allocation—learning about the dose–response as the trial progresses. Two scenarios: (A) single
drug in 8 doses; (B) two drugs in 3 and 4 doses, respectively. The 4 panels provide snapshots over time (i.: at start; iv.: at end of trial).
Bar charts to the left illustrate adaptive treatment allocation to different treatment arms over time. Figures to the right illustrate esti-
mated dose–response (surfaces) and learning over time. Response is a continuous variable, eg, change from baseline to day 90 on a
stroke scale (higher value indicates improvement). A, Single drug scenario: we start with no assumptions, ie, with a flat prior for the
estimate of the dose–response (black line). The blue line represents the true dose–response, which at the start of the trial is unknown
to us. With data coming in from the trial, we will be able to more accurately estimate the true dose–response. Red lines: 95% credible
intervals around estimated dose–response. B, Now we extend the methodology to two drugs. Think of “drug one” as a neuroprotectant
with little information about its dose–response (flat prior, identifiable as a dotted black line parallel to the “drug one” dose axis) and-
“drug two” as a thrombolytic with information about its dose–response (informative prior, identifiable as a curved dose—response,
black solid line, above the dose axis for “drug two” on the right edge of the dose–response surface). Collectively, the combination of
these assumed dose–responses form the prior dose–response surface (in color). In gray, the “true,” but initially unknown, dose–
response surface, which we want to identify. As we acquire more data, our estimate of the dose–response surface (in color) gets
updated and approaches the true dose–response surface with increasing accuracy. Vertical bars at each treatment cell indicate 95%
credible intervals around the mean estimated treatment effect.
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Seamless Designs
Traditionally, the time gap between a phase II dose–response
finding study and a confirmatory phase III trial can be 1
year. However, in the absence of major issues raised during
phase II, the transition from a learning phase to a confirma-
tory phase can occur seamlessly, with no pause in accrual.
Investigators may not even appreciate the change; they would
continue to get blinded dosing instructions.17 There could be
substantial savings in site set-up effort and opportunity costs.
With the creation of stroke trial networks, we may specu-
late to extend this idea further. Say that we could agree on the
most suitable primary endpoint and other key characteristics
for acute stroke trials. We then envisage conducting an
ongoing experiment with no clear beginning or end. New
therapeutic options are introduced as they mature from safety
testing, and patients are allocated to whatever treatment
promises maximal benefit to the overall stroke population.
This might sound futuristic, but in a rudimentary form such
designs are being implemented in oncology at M. D. Ander-
son Cancer Center.
Endpoints
Some clinical endpoints used in acute stroke trials (neurolog-
ical stroke scales, measures of functional outcome such as
modified Rankin score or Barthel Index) suffer from consid-
erable observer dependent variability. Any trial design would
benefit from endpoints with less variability. More meaningful
endpoints may evaluate improvement on an individual patient
basis rather than seeking a population response. The “re-
sponder” analysis used by the AbESTT investigators is an
example. Here, the threshold for favorable outcome is ad-
justed according to initial stroke severity. Patients with
National Institutes of Health Stroke Scale scores of 4 to 7
must achieve a final mRS of 0; patients with initial severity of
7 to 14 on National Institutes of Health Stroke Scale need to
achieve an mRS of 0 to 1; and more severely affected patients
are considered to have a favorable outcome with an mRS
score of 0 to 2.18 More sophisticated modeling of prognosis,
for example by using data from VISTA, is conceivable. Gain
functions integrating informative biomarkers (including im-
aging biochemical markers such as S100, etc) with centrally
assessed clinical endpoints may enhance trial efficiency.19 If
there are concerns regarding regulatory acceptability of novel
endpoints, we could discuss a strategy of using novel end-
points in the learning phase to inform adaptive treatment
allocation but switch to more conventional endpoints for the
final pivotal analysis.
Issues to Consider
Bayesian methods impose extra work. We need to assess and
quantify available information and plan for extensive model-
ing and simulation. Clinical trialists, biometricians, and
regulators must agree to take this approach. These experts
need to assess the scientific credibility of the models and
prior data.
The sequential design discussed relies on having at least
some degree of exchangeability among patients after taking
into consideration observed patient covariates. Bayesian
methods can deal with some lack of homogeneity such as
strong region and center effects, ie, a patient from a rural
clinic in India may differ from a patient in New York. There
may be time trends: nonpharmacological stroke therapy is
improving, with wider introduction of acute stroke units and
better management of risk factors. There may be accrual bias,
with physicians becoming partially unblinded to trial results,
eg, if a trial continues beyond the maximal sample size for the
exploratory phase in a seamless design, it could be inferred by
participating trialists that the project has not been stopped for
Figure 3. Continued
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futility. This is not necessarily a disadvantage, provided that
investigators cannot bias the treatment effect estimate, guar-
anteed through randomization and masking, there is no reason
to conceal accumulating evidence of potential worth of the
treatment undergoing study.
A badly formulated prior estimate can hinder a trial,
because the experiment then needs to overcome the weight of
incorrect data and assumptions. However, traditional trials
suffer in the same way from poor models or poor estimates of
standard error.
Well-chosen prior data and models for Bayesian designs
tend to lead to small trials, but trials can be large, precisely
when a large trial is necessary. In contrast, conventional trials
without continuous scrutiny of the data may come to their
predetermined end with an ambiguous conclusion.
Bayesian designs can make use of incoming data to inform
future decisions and thereby reduce potential delay. The
sooner a clinical endpoint reads out, the earlier it can impact
future decisions. When the final assessment of treatment
benefit occurs with some delay, such as in acute stroke trials,
in which it is traditionally assessed 3 months after treatment
start, longitudinal models can be help to predict final outcome
using earlier readouts or biomarkers (Figure 1).
Mechanics
With the advances in computer technology, large-scale clin-
ical trial simulations have become possible using sophisti-
cated algorithms. However, innovation has a cost. It requires
hard work, involving considerable upfront investment in
establishing the software, running simulations, and fine-
tuning the system for an optimal design to fulfill the user
requirements of the study.
In performing the trial, it is key to have an IDMC of
clinicians and statisticians knowledgeable in the specifics of
the design and able to overlook the performance of the system
as well as the usual concerns of IDMCs. Decisions regarding
the treatment allocation must happen in real time. The IDMC
reviews the performance of the system against predefined
user requirements. The decision regarding stopping the trial
requires IDMC endorsement: once the algorithm recom-
mends stopping, the IDMC will review the relevant informa-
tion. They may endorse the decision, but they may choose to
override the algorithm’s recommendation when there are
strong grounds for doing so.
The mechanics of real-time data captured through fax,
telephone, or Internet, have all been developed and require
integration into the infrastructure of data management and
trial logistics pertinent to large clinical trials.
Although it is particularly easy to administer a large
number of different doses with intravenous compounds in a
blinded fashion, it is also feasible to apply the principle to
oral compounds, for instance, combining 2 tablets that are
available at strengths of 0, 1, 3, and 4 allows 9
equidistant doses. There are similar schemes to cover a dose
range of 0 to 243 on a semi-logarithmic scale. Even where
drug supplies are limited by cost or manufacturing logistics,
it is possible to organize packaging in an efficient manner.
Early interactions with investigators, regulatory agencies,
and other parties involved in the conduct of trials have been
key to ensure the success of applying the Bayesian approach
in ASTIN. Our interactions with regulatory agencies have
been particularly rewarding. The Food and Drug Administra-
tion has recently staged workshops on Bayesian applications
(http://www.prous.com/bayesian2004/), supporting learning
about the approach and future applications where appropriate.
The Future
We have much to learn from the field of oncology. Bayesian
methods promise a seamless research process in which
preclinical data feed into clinical studies and in which phases
I, II, and III blend together, bringing treatment advances to
stroke patients as quickly and efficiently as possible. Al-
though we are accustomed to considering the concepts of
false-positives and false-negatives, we usually ignore the
more common problem of a “false neutral”: all the important
research questions that have not been investigated, simply
because a lack of efficiency of the scientific process. So
rather than consuming yet another 74 000 patients with only
marginal benefit to the overall population of stroke patients,
we envisage an ongoing definitive stroke trial, which learns in
real time about new treatments (or combination of treatments)
with adaptive shifting of resources toward the most convinc-
ing therapeutic approach, within (dose–response finding) and
across compounds. ASTIN has been a first step in this
direction. Bolder approaches looking at combination thera-
pies are currently being implemented and Figure 3B gives a
glimpse on what an adaptive design for establishing the best
combination of, for example, a fibrinolytic and a neuropro-
tectant might look like. Future designs may also include the
option of modifying the trial design itself. Possible modifi-
cations include stopping early, changing entry criteria, ex-
panding to additional sites, extending accrual beyond the
trial’s original sample size, or dropping or adding treatment
arms.
The greatest need for innovation and the greatest room for
improving drug development is effectively dealing with the
enormous numbers of potential drugs that are available for
development. The notion of developing drugs one at a time is
part of the pharmaceutical culture, but this will change.
Companies able to screen many drugs simultaneously and do
so effectively will survive, and others will not. Drugs that are
apparently more promising will move faster through the
preclinical setting. Drugs that give disappointing data will
languish.
There are two things we can do today. One is to share our
work experience and raw data to allow model-based ap-
proaches to clinical drug development (through VISTA). The
other is to be open-minded and willing to experiment with
innovations available today and be willing to embrace those
shown to be useful.17
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